products

Androskat^® is a medicine which is available as an ampoule and contains the active substance of papaverine hydrochloride. It is provided in a solution for injection form for intracavernous use. It is used in studies requiring artificial erection, such as Doppler/duplex ultrasonography. It is also used in treatment of erectile dysfunction. For more information about when to use this medicine, see the summary of product characteristics (SmPC).

Reference:
For all EU and EEA countries

Asacol^® is a medicine which contains the active substance mesalazine. It is available as gastro-resistant tablets (400mg & 800mg). It is used to treat mild to moderate ulcerative colitis both in acute phase and to prevent relapses. It is also used in the treatment of mildly to moderately active forms of Crohn’s disease both in the acute phase and to prevent its recurrences, insofar as the disease is limited to the colon. For more information about when to use this medicine, see the summary of product characteristics (SmPC).

Reference:
For all EU and EEA countries

Dridase^® is a medicine in the form of a syrup and contains the active substance of Oxybutynin hydrochloride. It is used to treat urinary incontinence, urge and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity). It is also used to treat nocturnal enuresis associated with detrusor overactivity, along with non-medicinal treatment, when other treatment has been unsuccessful. For more information about when to use this medicine, see the summary of product characteristics (SmPC).

Reference:
For all EU and EEA countries

Emselex^® is a medicine that contains the active substance darifenacin. It is available as prolonged-release tablets (7.5 mg and 15 mg). ‘Prolonged-release’ means that darifenacin is released slowly from the tablet over a few hours. Emselex^® is used in adults with overactive-bladder syndrome. It is used to treat the urge incontinence (sudden lack of control over urination), increased urinary frequency (need to urinate frequently) and urgency (sudden urge to pass urine) that are associated with the syndrome. For more information about when to use this medicine, see the summary of product characteristics (SmPC).

Reference:
EPAR (last updated 24/05/2013)
SmPC  – Product Information (last updated 09/02/2022)

Euphyllin^® is a medicine that contains the active substance theophylline. It is available as prolonged release capsule containing 100, 200, 300 and 400 mg theophylline and is used in the treatment of acute bronchial asthma attacks and reversible bronchospastic states associated with chronic bronchitis or emphysema. Theophylline should not be used as the first-choice treatment for the treatment of asthma in children. It is also used in the adjuvant treatment of paroxysmal dyspnea, acute pulmonary edema and other manifestations of heart failure. For more information about when to use this medicine, see the summary of product characteristics (SmPC).

Reference:
For all EU and EEA countries

Farydak^® contains the active substance panobinostat. Farydak^® is a cancer medicine used in combination with two other medicines, bortezomib and dexamethasone, to treat multiple myeloma (a cancer of the bone marrow). It is given to adults whose disease has come back or got worse after at least two previous treatments, including bortezomib and an immunomodulatory medicine (a medicine that acts on the immune system).

Because the number of patients with multiple myeloma is low, the disease is considered ‘rare’, and Farydak^® was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 November 2012. For more information about when to use this medicine, see the summary of product characteristics (SmPC).

For further information on Farydak please go to: https://global.farydak.com/

Reference:
EPAR (last updated 16/05/2023)
SMPC – Product Information (last updated 05/04/2022)

Further country specific information …AustriaDenmarkFinlandFranceGermanyGreeceIcelandNorwayPortugalSwedenUnited Kingdom

Levact^® is an anticancer medicine. It is used to treat the following types of cancer:

• chronic lymphocytic leukaemia (a cancer of a type of white blood cell called lymphocytes) in patients for whom treatment with fludarabine (another anticancer medicine) is not appropriate;
• non-Hodgkin’s lymphoma (a cancer of the lymph tissue, part of the immune system) in patients whose cancer got worse during or following treatment containing rituximab (another anticancer medicine);
• multiple myeloma (a cancer of the bone marrow) in combination with prednisone in patients older than 65 years who are not eligible for stem-cell transplantation and cannot be treated with thalidomide or bortezomib (other anticancer medicines).

The active substance in Levact^®, bendamustine hydrochloride, belongs to a group of anticancer medicines called ‘alkylating agents’. It binds to the DNA of cells while they are reproducing, which stops cell division. As a result, the cancer cells cannot divide and the growth of tumours slows down. For more information about when to use this medicine, see the summary of product characteristics (SmPC).

Reference:
For all EU and EEA countries
For non-EU countries please refer to your local health authority website.

Pegasys^® contains the active substance peginterferon alfa-2a. Pegasys^® is an antiviral medicine used to treat:

• chronic (long-term) hepatitis B in adults and children from 3 years of age
• chronic hepatitis C in adults and children from 5 years of age

Hepatitis B and C are diseases of the liver due to infection with the hepatitis B and C viruses, respectively. Pegasys^® is usually used alone for hepatitis B infection but is taken in combination with other medicines for hepatitis C. For more information about when to use this medicine in adults and children, see the summary of product characteristics (SmPC).

Reference:
EPAR (last updated 05/02/2018)
SmPC – Product Information (last updated 07/11/2022)
For non-EU countries please refer to your local health authority
For USA n.a.

For Canada – As previously supplied by Hoffmann-La Roche Limited, the pre-filled syringe is the only Pegasys^® format available from pharmaand GmbH and Accelera Pharma Canada Inc.

Pour le Canada – La seringue préremplie Pegasys^®, fournie auparavant par Hoffmann-La Roche Limited, est l’unique présentation disponible auprès de pharmaand GmbH et Accelera Pharma Canada Inc.